盘点:男性生殖健康研究盘点

2018-07-22 AlexYang MedSci原创

【1】Nat Commun:尿液中游离DNA是监测尿道感染的通用分析物 泌尿道感染是人类中最常见的感染之一。最近,有研究人员在细菌和病毒尿路感染中,测试了用尿液游离DNA(cfDNA)来全面监测宿主和病原微生物动态,并进行了相关研究。研究人员从141个尿液样本中分离出了cfDNA,这些尿液样本来自一个包含有82名肾移植患者的群体,并且进行了二代测序分析。研究发现,尿液cfDNA包含有


泌尿道感染是人类中最常见的感染之一。最近,有研究人员在细菌和病毒尿路感染中,测试了用尿液游离DNA(cfDNA)来全面监测宿主和病原微生物动态,并进行了相关研究。

研究人员从141个尿液样本中分离出了cfDNA,这些尿液样本来自一个包含有82名肾移植患者的群体,并且进行了二代测序分析。研究发现,尿液cfDNA包含有微生物组中细菌和病毒、药物敏感性、细菌生长动态、肾移植损伤和对感染的宿主响应的丰富的信息。这些不同层次的信息可以从一个单独的实验中获得,并且与基于实时定量PCR、传统的细菌培养和尿液分析相关的临床测试在个体水平上保持一致。另外,研究人员还指出,cfDNA阐释了症状发生的频率,并且在传统的诊断方法上并不能有效诊断

最后,研究人员指出,他们的工作鉴定了尿液cfDNA是监测尿路感染的一个高度通用分析物。


最近,有研究人员在一个代表性研究的泌尿道检查中,评估了客观的(拉长的)和主观的阴茎大小对勃起功能的影响。研究包括了689名年龄在35岁-70岁的男性。研究人员在多变量模型中利用逻辑回归和线性回归调查了IIEF-5调查问卷、身体检查(阴茎长度、前列腺体积、血压、身体质量指数-BMI)、代谢综合征(MS)、并发症、习惯(性交频率、身体活动、酒精和烟草使用情况)、教育水平、血糖、总睾丸素、雌二醇、PSA、血脂和自我认知(射精时间和主观阴茎大小)。

研究发现,客观阴茎平均长度为13.08cm±2.32,67名(9.72%)病人自我认为阴茎较小。76名(11.03%)参与者患有重度勃起功能障碍(ED),75名(10.88%)具有轻度到中等程度的ED,112名(16.25%)具有轻度ED,426名(61.83%)不患有ED。具有统计学显著意义的ED风险因子为自我认为阴茎较小(OR=2.23, 95% CI 1.35-3.69, p=.0017)、性交频率(每周)(OR=0.45, 95% CI 0.38-0.52, p<.0001)、令人满意的射精时间(no vs yes, OR=2.06, 95% CI 1.46-2.92, p<.0001)、并发症((yes vs. no, OR=2.01, 95% CI 1.46-2.76, p<.0001)、年龄大于65岁(OR=2.93, 95% CI 1.53-5.61, p<.0001)、抽烟(yes vs. no, OR=1.41, 95% CI 1.02-1.96, p<.0375)、常规身体运动(no vs. yes, OR=1.59, 95% CI 1.13-2.23, p<.0083)、血清总睾丸素小于200ng/dl(OR=3.48, 95% CI 1.69-7.16, p=0.0009)、血糖大于100mg/dl(OR=1.69, 95% CI 1.18-2.43, p=0.0044)和收缩压大于130mmHg(OR=1.60, 95% CI 1.16-2.19, p=0.0037)。

最后,研究人员指出,除了之前报道的风险因子,患者主观认为的阴茎大小能够负面的影响大约10%健康男性的性生活质量,而客观的阴茎大小对勃起功能的影响不具有显著影响。


在尿道重建外科手术中,对充分有效且"现成的"的移植物是非常需要的。目前,可利用的外科手术技术需要从自身部位获得移植物,这样也增加了外科手术并发症风险,并且增加了患者的不舒适程度。因此,在临床实践上,低成本且具有充分的再生潜力的无细胞移植物是非常有意义的。

无细胞管状胶原蛋白移植物跟君不同的胶原蛋白密度和纤维分布而有所区分,因此就产生了两极分化,即低纤维密度胶原蛋白移植物(LD-graft)和高纤维密度移植物(HD-graft),且研究人员将HD-graft作为对照。研究人员在将上述两种移植物移植到具有2厘米长医源性尿道缺陷兔子模型中来探究不同的作用。组织学阐释了移植了LD-graft的兔子比移植HD-graft具有更好的平滑肌再生情况。研究人员利用对比排尿式膀胱尿道造影术评估总的功能性结果,研究发现,在LD-graft中90%的患者尿道开放,而HD-graft中66.6%的患者尿道开放。另外,移植了LD-graft的动物模型成功交配的可能性更高,后代子孙也更加健康。

最后,研究人员指出,无细胞低密度极化胶原蛋白移植物在尿道再生上表现比高密度胶原蛋白移植物更好。


前列腺癌(PC)的放射治疗(RT)能够通过氧化胁迫引起神经血管结构的损伤,从而引起阴茎勃起功能障碍(ED)。最近,有研究人员评估了一种抗氧化剂-白藜芦醇在RT术后对ED的治疗效果。

研究包括了5个小组的50只小鼠,包括了对照组和长期的或短期的溶媒或者白藜芦醇治疗。研究人员还获取了阴茎海绵体组织来分析谷胱甘肽(GSH)、一氧化氮(NO)、环磷酸鸟苷(cGMP)、8-OHdG水平和超氧化物歧化酶(SOD)、半胱天冬酶-3活性、去乙酰化酶-1、Foxo-3、nNOS和eNOS蛋白表达情况。研究人员在长期治疗组测量了海绵体压力(ICP)。研究发现,在RT+长期溶媒治疗组中,组织GSH, NO, cGMP和SOD活性降低,而8-OHdg水平和半胱天冬酶-3活性增加。放射治疗能够引起去乙酰化酶-1、nNOS和eNOS蛋白表达的减少。然而,上述参数均可通过白藜芦醇治疗来进行恢复。另外,Foxo-3蛋白表达在RT+短期溶媒治疗组中没有改变,并且在RT+长期溶媒治疗组中作为一种防御机制增加;然而,白藜芦醇治疗能够引起Foxo-3表达的显著增加。

最后,研究人员指出,白藜芦醇能够维持勃起功能的代谢通路,并且还提供功能上的保护。因此,白藜芦醇可以作为一种治疗放射治疗后患者的维持勃起功能的补充药物。


佩罗尼氏疾病(PD)中的阴茎腹部弯曲并不是非常常见,但是能够导致性交方面的障碍,尤其是那些重度案例,即弯曲大于60度的患者。由于需要对尿道上皮进行处理而产生尿道并发症的顾虑,腹侧弯曲通常通过外科手术的折叠术来进行处理。

最近,有研究人员介绍了腹侧封闭技术在PD患者中阴茎腹侧弯曲修正中的应用。该手术的方法包括了神经血管术和尿道的移动。在阴茎弯曲表面最大程度的为止,研究人员进行部分的切除,并利用一个自我亲和的胶原绒(TachoSil®, Baxter, IL, USA)对产生的缺损部位进行封闭,并且不需要缝线固定。研究发现,平均的阴茎弯曲程度为98.3度(sd±27.6, 范围: 60-150)。平均的手术时间为99.2分钟(sd±12.4, 范围: 80-130)。平均的跟踪调查时间为17.9个月(sd±8.0, 范围: 9-29)。另外,12名患者中的10名(83.3%)表现出了笔直的阴茎。2名患者(16.7%)阴茎术后弯曲度小于30度,并且对性交不产生明显影响。所有的患者对性交质量都感到满意。

最后,研究人员指出,该腹侧封闭技术的初始结果是鼓舞人心的,但仍旧需要长期的数据来进一步鉴定。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1982702, encodeId=93f11982e02e4, content=<a href='/topic/show?id=8ac0e02482e' target=_blank style='color:#2F92EE;'>#男性生殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70248, encryptionId=8ac0e02482e, topicName=男性生殖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Oct 02 22:50:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304890, encodeId=0dda13048906a, content=<a href='/topic/show?id=c35069068ee' target=_blank style='color:#2F92EE;'>#生殖健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69068, encryptionId=c35069068ee, topicName=生殖健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506601, encodeId=2ecf150660171, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333386, encodeId=124833338682, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Jul 22 13:03:49 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333358, encodeId=6c5f33335859, content=需要加强研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 22 11:12:05 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333350, encodeId=67173333500e, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Sun Jul 22 11:04:16 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1982702, encodeId=93f11982e02e4, content=<a href='/topic/show?id=8ac0e02482e' target=_blank style='color:#2F92EE;'>#男性生殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70248, encryptionId=8ac0e02482e, topicName=男性生殖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Oct 02 22:50:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304890, encodeId=0dda13048906a, content=<a href='/topic/show?id=c35069068ee' target=_blank style='color:#2F92EE;'>#生殖健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69068, encryptionId=c35069068ee, topicName=生殖健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506601, encodeId=2ecf150660171, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333386, encodeId=124833338682, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Jul 22 13:03:49 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333358, encodeId=6c5f33335859, content=需要加强研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 22 11:12:05 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333350, encodeId=67173333500e, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Sun Jul 22 11:04:16 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1982702, encodeId=93f11982e02e4, content=<a href='/topic/show?id=8ac0e02482e' target=_blank style='color:#2F92EE;'>#男性生殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70248, encryptionId=8ac0e02482e, topicName=男性生殖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Oct 02 22:50:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304890, encodeId=0dda13048906a, content=<a href='/topic/show?id=c35069068ee' target=_blank style='color:#2F92EE;'>#生殖健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69068, encryptionId=c35069068ee, topicName=生殖健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506601, encodeId=2ecf150660171, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333386, encodeId=124833338682, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Jul 22 13:03:49 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333358, encodeId=6c5f33335859, content=需要加强研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 22 11:12:05 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333350, encodeId=67173333500e, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Sun Jul 22 11:04:16 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1982702, encodeId=93f11982e02e4, content=<a href='/topic/show?id=8ac0e02482e' target=_blank style='color:#2F92EE;'>#男性生殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70248, encryptionId=8ac0e02482e, topicName=男性生殖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Oct 02 22:50:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304890, encodeId=0dda13048906a, content=<a href='/topic/show?id=c35069068ee' target=_blank style='color:#2F92EE;'>#生殖健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69068, encryptionId=c35069068ee, topicName=生殖健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506601, encodeId=2ecf150660171, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333386, encodeId=124833338682, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Jul 22 13:03:49 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333358, encodeId=6c5f33335859, content=需要加强研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 22 11:12:05 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333350, encodeId=67173333500e, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Sun Jul 22 11:04:16 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-07-22 sunfeifeiyang

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1982702, encodeId=93f11982e02e4, content=<a href='/topic/show?id=8ac0e02482e' target=_blank style='color:#2F92EE;'>#男性生殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70248, encryptionId=8ac0e02482e, topicName=男性生殖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Oct 02 22:50:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304890, encodeId=0dda13048906a, content=<a href='/topic/show?id=c35069068ee' target=_blank style='color:#2F92EE;'>#生殖健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69068, encryptionId=c35069068ee, topicName=生殖健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506601, encodeId=2ecf150660171, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333386, encodeId=124833338682, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Jul 22 13:03:49 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333358, encodeId=6c5f33335859, content=需要加强研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 22 11:12:05 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333350, encodeId=67173333500e, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Sun Jul 22 11:04:16 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-07-22 医者仁心5538

    需要加强研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1982702, encodeId=93f11982e02e4, content=<a href='/topic/show?id=8ac0e02482e' target=_blank style='color:#2F92EE;'>#男性生殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70248, encryptionId=8ac0e02482e, topicName=男性生殖)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Oct 02 22:50:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304890, encodeId=0dda13048906a, content=<a href='/topic/show?id=c35069068ee' target=_blank style='color:#2F92EE;'>#生殖健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69068, encryptionId=c35069068ee, topicName=生殖健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2fe4321, createdName=lifangping, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506601, encodeId=2ecf150660171, content=<a href='/topic/show?id=529a2e90225' target=_blank style='color:#2F92EE;'>#健康研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27902, encryptionId=529a2e90225, topicName=健康研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59f9780892, createdName=hxq78319, createdTime=Tue Jul 24 01:50:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333386, encodeId=124833338682, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Jul 22 13:03:49 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333358, encodeId=6c5f33335859, content=需要加强研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jul 22 11:12:05 CST 2018, time=2018-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333350, encodeId=67173333500e, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Sun Jul 22 11:04:16 CST 2018, time=2018-07-22, status=1, ipAttribution=)]
    2018-07-22 AlexYang

    666

    0

相关资讯

JCO:同为乳腺癌患者,男女各有不同

男性乳腺癌约占所有乳腺癌新病例的1%,其分子生物学特征、治疗与结局的数据非常有限,人们对其了解主要来自乳腺癌女性的数据推断。

Diabetes Care:2型糖尿病与男性和女性肾细胞癌风险!

由此可见,该研究发现2型糖尿病与女性RCC的风险独立相关,而男性则无关。

PLoS One:低睾丸素水平男性中,睾丸素治疗和恶性前列腺癌风险研究

低睾丸素男性中的睾丸素治疗是非常常见的,并且尽管治疗周期短,该治疗方法还是使得人们对前列腺癌(CaP)风险的增加感到担忧。最近,有研究人员调查了持续适中睾丸素治疗与恶性CaP发生之间的关系。研究包括了2002年到2011年睾丸素水平低的患者,并且进行了前列腺特异性抗原(PSA)测试;排除了那些进行睾丸素治疗、前列腺或者乳腺癌、高PSA或者前列腺活检的患者。组织学确定的发生的恶性前列腺癌或者任何前列

JAMA:男性前列腺癌筛查也有危害?看推荐更新怎么说

发表在《JAMA》的一项由美国学者进行的评价,对2012年美国预防服务工作组(USPSTF)关于基于特定前列腺抗原(PSA)筛查前列腺癌的推荐进行了更新。

Diabetic Med:生活满意度是预防男性2型糖尿病发病的保护因素?

近日,国际杂志 《Diabetic Med》上在线发表一项关于生活满意度是预防男性2型糖尿病发病的保护因素,而对于女性却不是:MONICA / KORA队列研究的结果。研究目的是调查2型糖尿病男女患者对高生活满意度与2型糖尿病的相关性。 研究对象包括在1989-1995随访至2009年的两次基于人群的MONICA / KORA调查的7107名参与者(3664名男性,51.5%; 3443名女

男性的“沉默杀手”—前列腺癌

由于环境质量下降和饮食结构不合理等因素,促使前列腺癌成为男性健康的又一“杀手”。 其发病率具有明显的地理和种族差异,在欧美男性中极高,目前美国前列腺癌发病率稳定在104/每十万男性人口。在我国,前列腺癌也是近十年来发病率上升最快的肿瘤,并出现年轻化趋向,预计2030年,我国前列腺癌新发患者数量将达到23.7万人,新发患者数量的年复合增长率将为5%。从全球范围来看,发达国家的前列腺癌发病率高于